{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T22:25:39Z","timestamp":1792016739900,"version":"4.4.0"},"reference-count":76,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T00:00:00Z","timestamp":1660003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>RNA-delivery is a promising tool to develop therapies for difficult to treat diseases such as neurological disorders, by silencing pathological genes or expressing therapeutic proteins. However, in many cases RNA delivery requires a vesicle that could effectively protect the molecule from bio-degradation, bypass barriers i.e., the blood brain barrier, transfer it to a targeted tissue and efficiently release the RNA inside the cells. Many vesicles such as viral vectors, and polymeric nanoparticles have been mentioned in literature. In this review, we focus in the discussion of lipid-based advanced RNA-delivery platforms. Liposomes and lipoplexes, solid lipid nanoparticles and lipid nanoparticles are the main categories of lipidic platforms for RNA-delivery to the central nervous systems (CNS). A variety of surface particles\u2019 modifications and routes of administration have been studied to target CNS providing encouraging results <jats:italic>in vivo<\/jats:italic>. It is concluded that lipid-based nanoplatforms will play a key role in the development of RNA neuro-therapies.<\/jats:p>","DOI":"10.3389\/fphar.2022.900610","type":"journal-article","created":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T05:09:01Z","timestamp":1660021741000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":40,"title":["Lipid-based nanoparticles and RNA as innovative neuro-therapeutics"],"prefix":"10.3389","volume":"13","author":[{"given":"Maria","family":"Tsakiri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Zivko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Costas","family":"Demetzos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Mahairaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1021\/acschemneuro.0c00076","article-title":"GLUT-1: an effective target to deliver brain-derived neurotrophic factor gene across the blood brain barrier","volume":"11","author":"Arora","year":"2020","journal-title":"ACS Chem. Neurosci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e0219995","DOI":"10.1371\/journal.pone.0219995","article-title":"PrPC knockdown by liposome-siRNA-peptide complexes (LSPCs) prolongs survival and normal behavior of prion-infected mice immunotolerant to treatment","volume":"14","author":"Bender","year":"2019","journal-title":"PLoS One"},{"key":"B4","doi-asserted-by":"publisher","first-page":"54106","DOI":"10.3791\/54106","article-title":"Delivery of therapeutic siRNA to the CNS using cationic and anionic liposomes","author":"Bender","year":"2016","journal-title":"J. Vis. Exp."},{"key":"B5","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.ejpb.2018.05.009","article-title":"Recent advances in carrier mediated nose-to-brain delivery of pharmaceutics","volume":"128","author":"Bourganis","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"B6","doi-asserted-by":"publisher","first-page":"5789","DOI":"10.3390\/molecules25245789","article-title":"Comprehensive review on Alzheimer\u2019s disease: Causes and treatment","volume":"25","author":"Breijyeh","year":"2020","journal-title":"Molecules"},{"key":"B7","doi-asserted-by":"publisher","first-page":"5995","DOI":"10.2147\/IJN.S87334","article-title":"Investigation of enzyme-sensitive lipid nanoparticles for delivery of siRNA to blood\u2013brain barrier and glioma cells","volume":"10","author":"Bruun","year":"2015","journal-title":"Int. J. Nanomedicine"},{"key":"B8","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","article-title":"Viral vector platforms within the gene therapy landscape","volume":"6","author":"Bulcha","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jconrel.2008.08.014","article-title":"Tf-lipoplexes for neuronal siRNA delivery: a promising system to mediate gene silencing in the CNS","volume":"132","author":"Cardoso","year":"2008","journal-title":"J. Control. Release"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1021\/nn506248s","article-title":"Localized RNAi therapeutics of chemoresistant grade IV glioma using hyaluronan-grafted lipid-based nanoparticles","volume":"9","author":"Cohen","year":"2015","journal-title":"ACS Nano"},{"key":"B11","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.lfs.2017.12.025","article-title":"Mechanism of intranasal drug delivery directly to the brain","volume":"195","author":"Crowe","year":"2018","journal-title":"Life Sci."},{"key":"B12","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1039\/C8TX00005K","article-title":"Correlation of the cytotoxic effects of cationic lipids with their headgroups","volume":"7","author":"Cui","year":"2018","journal-title":"Toxicol. Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"6553","DOI":"10.2174\/1381612824666171128105305","article-title":"Intranasal lipid nanoparticles for the treatment of neurodegenerative diseases","volume":"23","author":"Cunha","year":"2017","journal-title":"Curr. Pharm. Des."},{"key":"B14","doi-asserted-by":"publisher","first-page":"628137","DOI":"10.3389\/fbioe.2021.628137","article-title":"The limitless future of RNA therapeutics","volume":"9","author":"Damase","year":"2021","journal-title":"Front. Bioeng. Biotechnol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1038\/d41586-019-03068-4","article-title":"RNA therapies explained","volume":"574","author":"DeWeerdt","year":"2019","journal-title":"Nature"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1021\/acs.molpharmaceut.0c00170","article-title":"Intranasal delivery and transfection of mRNA therapeutics in the brain using cationic liposomes","volume":"17","author":"Dhaliwal","year":"2020","journal-title":"Mol. Pharm."},{"key":"B17","doi-asserted-by":"publisher","first-page":"446","DOI":"10.3390\/pharmaceutics13040446","article-title":"Non-viral gene delivery systems","volume":"13","author":"Faneca","year":"2021","journal-title":"Pharmaceutics"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.drudis.2018.01.005","article-title":"An update on the role of nanovehicles in nose-to-brain drug delivery","volume":"23","author":"Feng","year":"2018","journal-title":"Drug Discov. Today"},{"key":"B19","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/s0005-2736(97)00126-0","article-title":"Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells","volume":"1329","author":"Filion","year":"1997","journal-title":"Biochim. Biophys. Acta"},{"key":"B20","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1126\/science.175.4025.949","article-title":"Gene therapy for human genetic disease?","volume":"175","author":"Friedmann","year":"1972","journal-title":"Science"},{"key":"B21","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jconrel.2017.11.041","article-title":"Nanoparticulate peptide delivery exclusively to the brain produces tolerance free analgesia","volume":"270","author":"Godfrey","year":"2018","journal-title":"J. Control. Release"},{"key":"B22","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1080\/1061186X.2018.1502775","article-title":"Effect of cationic lipid in cationic liposomes on siRNA delivery into the lung by intravenous injection of cationic lipoplex","volume":"27","author":"Hattori","year":"2019","journal-title":"J. Drug Target."},{"key":"B23","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.actbio.2021.10.042","article-title":"Core-shell lipoplexes inducing active macropinocytosis promote intranasal delivery of c-Myc siRNA for treatment of glioblastoma","volume":"138","author":"Hu","year":"2022","journal-title":"Acta Biomater."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2568","DOI":"10.1021\/bc200406n","article-title":"In vivo specific delivery of c-met siRNA to glioblastoma using cationic solid lipid nanoparticles","volume":"22","author":"Jin","year":"2011","journal-title":"Bioconjug. Chem."},{"key":"B25","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1208\/s12248-021-00648-z","article-title":"Understanding drug delivery to the brain using liposome-based strategies: Studies that provide mechanistic insights are essential","volume":"23","author":"Juhairiyah","year":"2021","journal-title":"AAPS J."},{"key":"B26","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1002\/ana.24789","article-title":"RNAi prevents and reverses phenotypes induced by mutant human ataxin-1","volume":"80","author":"Keiser","year":"2016","journal-title":"Ann. Neurol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1208\/s12248-021-00653-2","article-title":"Development of lipidoid nanoparticles for siRNA delivery to neural cells","volume":"24","author":"Khare","year":"2021","journal-title":"AAPS J."},{"key":"B28","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.nano.2014.08.004","article-title":"In vivo toxicity of cationic micelles and liposomes","volume":"11","author":"Knudsen","year":"2015","journal-title":"Nanomedicine"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.2147\/IJN.S239608","article-title":"Transferrin-modified osthole PEGylated liposomes travel the blood-brain barrier and mitigate alzheimer\u2019s disease-related pathology in APP\/PS-1 mice","volume":"15","author":"Kong","year":"2020","journal-title":"Int. J. Nanomedicine"},{"key":"B30","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/s41565-021-00898-0","article-title":"The current landscape of nucleic acid therapeutics","volume":"16","author":"Kulkarni","year":"2021","journal-title":"Nat. Nanotechnol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/nature05901","article-title":"Transvascular delivery of small interfering RNA to the central nervous system","volume":"448","author":"Kumar","year":"2007","journal-title":"Nature"},{"key":"B32","doi-asserted-by":"publisher","first-page":"113851","DOI":"10.1016\/j.addr.2021.113851","article-title":"Liposome composition in drug delivery design, synthesis, characterization, and clinical application","volume":"176","author":"Large","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B33","doi-asserted-by":"publisher","first-page":"270","DOI":"10.3390\/nano8050270","article-title":"Cationic liposomes carrying siRNA: Impact of lipid composition on physicochemical properties, cytotoxicity and endosomal escape","volume":"8","author":"Lechanteur","year":"2018","journal-title":"Nanomaterials"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e479","DOI":"10.1016\/S2666-7568(21)00140-9","article-title":"Mortality rates in Alzheimer\u2019s disease and non-alzheimer\u2019s dementias: a systematic review and meta-analysis","volume":"2","author":"Liang","year":"2021","journal-title":"Lancet Healthy Longev."},{"key":"B35","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.omtm.2020.07.015","article-title":"Barriers and strategies of cationic liposomes for cancer gene therapy","volume":"18","author":"Liu","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"B36","doi-asserted-by":"publisher","first-page":"E42","DOI":"10.3390\/diseases6020042","article-title":"Viral vectors in gene therapy","volume":"6","author":"Lundstrom","year":"2018","journal-title":"Diseases"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1039\/c7bm00712d","article-title":"A new developing class of gene delivery: messenger RNA-based therapeutics","volume":"5","author":"Meng","year":"2017","journal-title":"Biomater. Sci."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1016\/j.drudis.2022.01.003","article-title":"Role of siRNA-based nanocarriers for the treatment of neurodegenerative diseases","volume":"27","author":"Mishra","year":"2022","journal-title":"Drug Discov. Today"},{"key":"B41","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/d41586-021-03410-9","article-title":"More Alzheimer\u2019s drugs head for FDA review: What scientists are watching","volume":"599","author":"Mullard","year":"2021","journal-title":"Nature"},{"key":"B42","doi-asserted-by":"publisher","first-page":"305","DOI":"10.15171\/apb.2015.043","article-title":"Solid lipid nanoparticles and nanostructured lipid carriers: structure, preparation and application","volume":"5","author":"Naseri","year":"2015","journal-title":"Adv. Pharm. Bull."},{"key":"B43","first-page":"10","article-title":"Report and recommendations of the panel to assess the NIH investment in research on gene therapy","volume":"116","author":"Orkin","year":"1996","journal-title":"Bull. Med. Ethics"},{"key":"B44","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s12035-021-02555-y","article-title":"Gene therapy approach with an emphasis on growth factors: theoretical and clinical outcomes in neurodegenerative diseases","volume":"59","author":"Parambi","year":"2022","journal-title":"Mol. Neurobiol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"5491","DOI":"10.3390\/ijms20215491","article-title":"The development of functional non-viral vectors for gene delivery","volume":"20","author":"Patil","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B46","doi-asserted-by":"publisher","first-page":"4677","DOI":"10.1016\/j.bmc.2018.08.006","article-title":"Dual-targeting for brain-specific liposomes drug delivery system: synthesis and preliminary evaluation","volume":"26","author":"Peng","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"B47","doi-asserted-by":"publisher","first-page":"989","DOI":"10.3390\/pharmaceutics13070989","article-title":"Lipoplexes to deliver oligonucleotides in gram-positive and gram-negative bacteria: towards treatment of blood infections","volume":"13","author":"Pereira","year":"2021","journal-title":"Pharmaceutics"},{"key":"B48","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ejpb.2020.08.010","article-title":"Cationic lipid\/pDNA complex formation as potential generic method to generate specific IRF pathway stimulators","volume":"155","author":"Putzke","year":"2020","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"B50","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.ejmech.2013.10.007","article-title":"Design, synthesis and biological evaluation of multivalent glucosides with high affinity as ligands for brain targeting liposomes","volume":"72","author":"Qu","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"B51","doi-asserted-by":"publisher","first-page":"e6810","DOI":"10.1371\/journal.pone.0006810","article-title":"MECP2 isoform-specific vectors with regulated expression for rett syndrome gene therapy","volume":"4","author":"Rastegar","year":"2009","journal-title":"PLoS One"},{"key":"B52","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.colsurfb.2017.01.031","article-title":"Nose-to-brain delivery of BACE1 siRNA loaded in solid lipid nanoparticles for Alzheimer\u2019s therapy","volume":"152","author":"Rassu","year":"2017","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"B53","doi-asserted-by":"publisher","first-page":"e136","DOI":"10.1038\/mtna.2013.65","article-title":"Lipid nanoparticle delivery of siRNA to silence neuronal gene expression in the brain","volume":"2","author":"Rungta","year":"2013","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"B54","doi-asserted-by":"publisher","first-page":"3705","DOI":"10.2147\/DDDT.S85302","article-title":"Targeting brain cells with glutathione-modulated nanoliposomes: In vitro and in vivo study","volume":"9","author":"Salem","year":"2015","journal-title":"Drug Des. devel. Ther."},{"key":"B55","doi-asserted-by":"publisher","first-page":"587997","DOI":"10.3389\/fmolb.2020.587997","article-title":"Solid lipid nanoparticles for drug delivery: pharmacological and biopharmaceutical aspects","volume":"7","author":"Scioli Montoto","year":"2020","journal-title":"Front. Mol. Biosci."},{"key":"B56","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1089\/hum.2020.054","article-title":"Detailed protocol for the novel and scalable viral vector upstream process for AAV gene therapy manufacturing","volume":"32","author":"Selvaraj","year":"2021","journal-title":"Hum. Gene Ther."},{"key":"B57","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S0140-6736(16)30374-9","article-title":"Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1\/2 trial","volume":"388","author":"Sessa","year":"2016","journal-title":"Lancet"},{"key":"B58","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s13311-018-00694-0","article-title":"Gene therapy for neurodegenerative diseases","volume":"16","author":"Sudhakar","year":"2019","journal-title":"Neurotherapeutics"},{"key":"B59","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/s41593-020-00778-1","article-title":"Gene-based therapies for neurodegenerative diseases","volume":"24","author":"Sun","year":"2021","journal-title":"Nat. Neurosci."},{"key":"B60","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1021\/acs.molpharmaceut.7b01084","article-title":"In vivo introduction of mRNA encapsulated in lipid nanoparticles to brain neuronal cells and astrocytes via intracerebroventricular administration","volume":"15","author":"Tanaka","year":"2018","journal-title":"Mol. Pharm."},{"key":"B61","doi-asserted-by":"publisher","first-page":"521","DOI":"10.15585\/mmwr.mm6620a1","article-title":"Deaths from Alzheimer\u2019s disease\u2014United States, 1999\u20132014","volume":"66","author":"Taylor","year":"2017","journal-title":"MMWR. Morb. Mortal. Wkly. Rep."},{"key":"B62","doi-asserted-by":"publisher","first-page":"16982","DOI":"10.1021\/acsnano.1c04996","article-title":"Lipid Nanoparticles\u2500From liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement","volume":"15","author":"Tenchov","year":"2021","journal-title":"ACS Nano"},{"key":"B63","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ejpb.2021.07.015","article-title":"Dopamine-loaded lipid based nanocarriers for intranasal administration of the neurotransmitter: a comparative study","volume":"167","author":"Trapani","year":"2021","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"B64","doi-asserted-by":"publisher","first-page":"121212","DOI":"10.1016\/j.ijpharm.2021.121212","article-title":"Innovative vaccine platforms against infectious diseases: under the scope of the COVID-19 pandemic","volume":"610","author":"Tsakiri","year":"2021","journal-title":"Int. J. Pharm."},{"key":"B65","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"B66","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.3390\/molecules25122866","article-title":"Role of lipid-based and polymer-based non-viral vectors in nucleic acid delivery for next-generation gene therapy","volume":"25","author":"Wahane","year":"2020","journal-title":"Molecules"},{"key":"B67","doi-asserted-by":"publisher","first-page":"249","DOI":"10.2165\/00003495-200060020-00002","article-title":"Viral vectors for gene transfer: a review of their use in the treatment of human diseases.","volume":"60","author":"Walther","year":"2000","journal-title":"Drugs"},{"key":"B68","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1111\/jnc.14588","article-title":"Regulating nociceptive transmission by VGluT2-expressing spinal dorsal horn neurons","volume":"147","author":"Wang","year":"2018","journal-title":"J. Neurochem."},{"key":"B69","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.3390\/v13122502","article-title":"Adenovirus biology, recombinant adenovirus, and adenovirus usage in gene therapy","volume":"13","author":"Watanabe","year":"2021","journal-title":"Viruses"},{"key":"B70","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/alz.12328","article-title":"Alzheimer\u2019s disease facts and figures","volume":"17","author":"Wiley","year":"2021","journal-title":"Alzheimers Dement."},{"key":"B71","doi-asserted-by":"publisher","first-page":"27361","DOI":"10.1039\/C8CP05905E","article-title":"The effect of electrostatic interactions on the formation of pharmaceutical eutectics","volume":"20","author":"Wojnarowska","year":"2018","journal-title":"Phys. Chem. Chem. Phys."},{"key":"B72","doi-asserted-by":"publisher","first-page":"134ra61","DOI":"10.1126\/scitranslmed.3003640","article-title":"Gene therapy for aromatic l-amino acid decarboxylase deficiency","volume":"4","author":"Wuh-Liang","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"B73","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s11060-018-2966-6","article-title":"Inhibition of glioma growth by a GOLPH3 siRNA-loaded cationic liposomes","volume":"140","author":"Yuan","year":"2018","journal-title":"J. Neurooncol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/978-1-62703-140-0_17","article-title":"Lipopeptide delivery of siRNA to the central nervous system","volume":"948","author":"Zabel","year":"2013","journal-title":"Methods Mol. Biol."},{"key":"B75","first-page":"13","article-title":"Chapter two - lipid nanoparticles for gene delivery","volume-title":"Nonviral vectors for gene therapy","author":"Zhao","year":"2014"},{"key":"B76","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","article-title":"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"396","author":"Zhu","year":"2020","journal-title":"Lancet"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.900610\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T05:09:05Z","timestamp":1660021745000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.900610\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,9]]},"references-count":76,"alternative-id":["10.3389\/fphar.2022.900610"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.900610","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,9]]},"article-number":"900610"}}